(Q34253090)

31 July 2017

title

The innovative medicines initiative: a European response to the innovation challenge (English)

1 reference

31 July 2017

M Goldman

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

8 February 2012

1 reference

Clinical Pharmacology & Therapeutics

31 July 2017

published in

1 reference

31 July 2017

volume

91

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

418-425

1 reference

The importance of new companies for drug discovery: origins of a decade of new drugs

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Power to the people: participant ownership of clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

The missing voice of patients in drug-safety reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Enhancing ties between academia and industry to improve health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Open innovation networks between academia and industry: an imperative for breakthrough therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

A flexible blueprint for the future of drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Time to 'walk the walk' about industry ties to enhance health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Virtual drug discovery and development for neglected diseases through public-private partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Reaching maturity - 25 years of the TDR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Can open-source drug R&D repower pharmaceutical innovation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

The FDA critical path initiative and its influence on new drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Translational toxicology and the work of the predictive safety testing consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Schizophrenia: The drug deadlock

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

CXCL5 mediates UVB irradiation-induced pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

An integrative systems biology approach to understanding pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

A generic operational strategy to qualify translational safety biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

A multiscale simulation system for the prediction of drug-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Shaping the future of safer innovative drugs in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Reflections on the Innovative Medicines Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Commercialization and collaboration: competing policies in publicly funded stem cell research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Network dynamics to evaluate performance of an academic institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

"Creating hope" and other incentives for drug development for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

The Precompetitive Space: Time to Move the Yardsticks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

How to improve R&D productivity: the pharmaceutical industry's grand challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

European perspective on risk management and drug safety

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

Biomedical research and health advances

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

Precompetitive research: a new prescription for drug development?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

How to revive breakthrough innovation in the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

Pharma embraces open source models

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

1 reference

7 January 2021

Defining success for translational research organizations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

Development of novel combination therapies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

Regulatory science: what it is and why we need it

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.321

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.321

1 reference

31 July 2017

1 reference